Such changes may compromise subsequent treatment efficacy, as higher TCR affinity and avidity CD8+ TILs are associated with better tumour clearance in anti-PD-1-treated patients54,55 and superior tumour infiltration and control after adoptive cell therapy56. This evidence concerns the gene CD8A and neoplasm.